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Background
Within the Köln/Bonn cohort, all IFN/RBV-treated HIV/
HCV co-infected patients were evaluated for treatment
outcome and possible predictive factors for achieving cure
of HCV infection defined as undetectable HCV-RNA 24
weeks upon completion of HCV therapy (SVR).
Methods
Patients included in this retrospective multicentre cohort
study received peg-IFN (1.5 μg/kg body weight or 180 μg,
respectively) once weekly and weight-based RBV (600–
1200 mg) once daily. Patients with HCV-genotypes 2 or 3
were treated for 24 or 48 weeks; patients with genotype 1
or 4 received 48 weeks of therapy. Primary end-point was
SVR. Binary logistic regression and calculation of positive
predictive values (PPV) were used to identify prognostic
parameters for achieving SVR and EVR (early virological
response defined as undetectable HCV-RNA after 12
weeks of IFN/RBV treatment), respectively.
Summary of results
A total of 227 HIV/HCV co-infected patients were
included. Patients were predominantly male (73%),
mean age was 41 years, 59,5% received HAART. The dis-
tribution of HCV-genotypes (GT) was as follows: GT 1:
56%, GT 2: 6%, GT 3: 31%, GT 4: 7%. Further baseline
characteristics (median) were: CD4-count 531/μL (26%),
HIV-RNA 11.635 cps/mL, HCV-RNA 2.444.870 IU/mL,
ALT 69 U/L, Hb 14.4 g/dL, leucocytes 5810/μL, platelets
190/nL. SVR was achieved by 41% (GT 1/4: 32%; GT 2/3:
59%) of all patients. HCV-GT 2 or 3 (p < 0.001, 95% con-
fidence interval [CI] 2.19 to 8.02; PPV 67.82%), rapid
virological response (RVR, defined as undetectable serum-
RNA at week 4) (p < 0.001, CI 5.42 to 44.36; PPV 83.78%)
and EVR (p < 0.001, CI 6.71 to 26.01; PPV 71.56%) were
the best independent predictors for achieving SVR. Posi-
tive predictives for EVR were HCV-GT 2 or 3 (p < 0.001, CI
2.81 to 10.55; PPV 78.68%), RVR (p < 0.001, CI 3.36 to
24.24; PPV 87.23%) and the lack of HAART (p = 0.043, CI
0.28 to 0.98; PPV 64.82%).
Conclusion
The most reliable predictive factor for achieving sustained
virological response in HIV/HCV co-infected patients
treated with peg-IFN plus RBV is to obtain rapid virologi-
cal response. Further positive predictives for obtaining
SVR are infection with HCV-GT 2 or 3 and early virologi-
cal response (EVR). Positive predictive factors for obtain-
ing EVR are again HCV infection with GT 2 or 3, RVR and,
interestingly, also stable HIV infection without a need for
HAART therapy.
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